English Community

This is an interesting publication. Has anyone's tumor ever been tested  for a molecule called MHC class II? I had tumor profiling done at Princess Margaret and they didn't test for that molecule. I would be interested in knowing. 

Cancer cells surprised scientists - the body's own defense may be the key to longer survival

A new study sheds light on why some patients with the most aggressive form of ovarian cancer respond better to treatment than others. Tumors positive for a molecule called MHC class II are linked to stronger immune responses and longer survival.

These findings from a large study led by the University of Helsinki highlight how certain ovarian cancer cells can shape the immune response around them, offering clues that may help refine prognosis and future therapies.

By closely examining ovarian cancer tissue from more than 280 women, researchers discovered that patients tended to do better when immune cells gathered in groups at the edge of the tumor, where cancer meets healthy tissue. This border area turned out to be a crucial place where the body's defence tries to stop the disease from spreading.

The findings show that cancer cells can influence how the immune system behaves nearby, and that this "front line" is where the most important battles between the tumor and the body take place.

"We were able to create detailed maps of over 1000 ovarian cancer tissues, zooming in on individual cells and how they are arranged. This powerful imaging approach showed that the immune system was already fighting back - we just didn't know how to see it before," says the study's lead researcher, specialist in gynecology Anniina Färkkilä from the University of Helsinki.

One of the most important discoveries involved a molecule called MHC class II. Normally used by immune cells to alert the body to external threats, this molecule was also found on some cancer cells. Tumors with higher levels of MHC class II were linked to stronger immune responses and more favorable outcomes, independently of traditional clinical or molecular risk factors.

These results position MHC class II as a key molecular signal linked to longer survival.

To test what this means for treatment, researchers used tumor samples grown from patients in the lab. When these tumors carried MHC class II, immune cells were better able to attack the cancer after immunotherapy. When the signal was blocked, the immune response weakened. 

This suggests that immunotherapies work better for patients whose tumours express MHC class II, and that we can use MHC class II as a marker to select patients for these treatments in the clinics. Boosting MHC class II could also be a way to make patients respond to immunotherapies. 

"We were surprised to see cancer cells using a signal normally reserved for the immune system," said Anniina Färkkilä. "This marker helps explain why some patients' immune systems recognize and fight their tumors more effectively, and it helps us to better treat ovarian cancer with immunotherapy in the future."

The findings, published in Cancer Discovery, a journal of the American Association for Cancer Research, on February 9, 2026, demonstrate how we can harness the immune system and apply more personalized treatment approaches in ovarian cancer. 

Hi @Cole ... thanks for sharing this information. I'm treated out of PMH as well and I went back to look at my genetic test report. My testing did not include MHC. I'm wondering if it's because it's not a "standard" biomarker that is tested for. I know that my genetic testing was done with my permission.  A geneticist reviewed the results with me however I will admit it was so soon after my surgery and I my head was still so confused as to what was going on that I'm sure I didn't absorb everything. For those of us that have had genetic testing done, we should always feel comfortable asking what was tested and how they determine what to test for. I learned from the recent OCC Biomarker Speaker Series event, if warranted there can sometimes be 'secondary' testing done on tumour samples. Perhaps like myself, when we are in a better place to understand and absorb information, a revisit of our genetic test results with our medical team would be of value. That is of course a personal choice. 

I'm also going to share these research findings with my soon to be daughter-in-law who is a PhD candidate in Molecular Science and whose focus is on ovarian cancer. I'd be curious to see if she has seen the report and what her perspective is. 

Regardless, it is good to see ongoing research from around the globe. I'm always thankful that there is continued focus on treatment of ovarian cancer. A cure is out there!!! Thanks again for sharing.

#Clinicaltrialsandresearch

I had Genetic testing done plus tumour profiling and both of them didn't even include MHC Class II Molecule testing. I will mention it to PM at our next follow up!